Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Operating Expenses: 2019-2025

Historic Other Operating Expenses for Coherus Oncology (CHRS) over the last 7 years, with Sep 2025 value amounting to $3.7 million.

  • Coherus Oncology's Other Operating Expenses rose 36.35% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 264.70%. This contributed to the annual value of $117.6 million for FY2024, which is 141.31% up from last year.
  • Per Coherus Oncology's latest filing, its Other Operating Expenses stood at $3.7 million for Q3 2025, which was up 9.60% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Other Operating Expenses peaked at $111.6 million during Q4 2024, and registered a low of -$108.5 million during Q3 2022.
  • Over the past 3 years, Coherus Oncology's median Other Operating Expenses value was $2.7 million (recorded in 2024), while the average stood at $3.6 million.
  • Per our database at Business Quant, Coherus Oncology's Other Operating Expenses plummeted by 745.25% in 2022 and then soared by 240.08% in 2024.
  • Over the past 5 years, Coherus Oncology's Other Operating Expenses (Quarterly) stood at $12.1 million in 2021, then crashed by 745.25% to -$78.1 million in 2022, then declined by 1.99% to -$79.7 million in 2023, then spiked by 240.08% to $111.6 million in 2024, then spiked by 36.35% to $3.7 million in 2025.
  • Its Other Operating Expenses was $3.7 million in Q3 2025, compared to $3.4 million in Q2 2025 and $2.7 million in Q1 2025.